Atherosclerosis
Volume 210, Issue 1 , Pages 28-34 , May 2010

Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

  • Muriel J. Caslake

      Affiliations

    • Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
    • Corresponding Author InformationCorresponding author at: Vascular Biochemistry Group, University of Glasgow, Western Infirmary Glasgow, 2nd Floor McGregor Building, Glasgow G11 6NT, UK. Tel.: +44 141 211 2161; fax: +44 141 232 9516.
    • ,
  • Chris J. Packard

      Affiliations

    • Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
    • ,
  • Michele Robertson

      Affiliations

    • Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
    • ,
  • Josephine Cooney

      Affiliations

    • Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
    • ,
  • Jeanenne J. Nelson

      Affiliations

    • Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC, USA
    • ,
  • Ian Ford

      Affiliations

    • Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
    • ,
  • Allan Gaw

      Affiliations

    • Glasgow Clinical Research Facility, NHS Greater Glasgow & Clyde, UK
    • ,
  • J. Wouter Jukema

      Affiliations

    • Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands
    • ,
  • Peter W. Macfarlane

      Affiliations

    • Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
    • ,
  • David J. Stott

      Affiliations

    • Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
    • ,
  • James Shepherd

      Affiliations

    • Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
    • ,
  • for the PROSPER Study Group

Received 17 April 2009 ,Revised 15 October 2009 ,Accepted 29 October 2009.

References 

  1. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II2–II10
  2. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397
  3. Mora S, Rifai N, Buring JE, Ridker PM. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation. 2006;114:381–387
  4. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166:1368–1373
  5. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol. 2004;44:1945–1956
  6. Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001;358:971–976
  7. Rosengren B, Jonsson-Rylander AC, Peilot H, Camejo G, Hurt-Camejo E. Distinctiveness of secretory phospholipase A(2) group IIA and V suggesting unique roles in atherosclerosis. Biochim Biophys Acta. 2006;1761:1301–1308
  8. Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148–1155
  9. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837–842
  10. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26:1586–1593
  11. O’Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006;113:1745–1752
  12. Zalewski A, Macphee C, Nelson JJ. Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:527–532
  13. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570–575
  14. Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007;82:159–165
  15. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41:37S–42S
  16. Chen C-H. Platelet-activating factor acetylhydrolase:is it good or bad for you?. Curr Opin Lipidol. 2004;15:337–341
  17. Ford I, Blauw GJ, Murphy MB, et al. A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): screening experience and baseline characteristics. Curr Control Trials Cardiovasc Med. 2002;3:8
  18. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  19. Packard CJ, Ford I, Robertson M, et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2005;112:3058–3065
  20. Sattar N, Murray HM, McConnachie A, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2007;115:981–989
  21. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903–1908
  22. Brilakis ES, McConnell JP, Lennon RJ, et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137–144
  23. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med. 2005;2:529–535
  24. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165:2479–2484
  25. van Vark LC, Kardys I, Bleumink GS, et al. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study. Eur Heart J. 2006;27:2346–2352
  26. Iribarren C, Gross MD, Darbinian JA, et al. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol. 2005;25:216–221
  27. Yang EH, McConnell JP, Lennon RJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2006;26:106–111
  28. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2523–2529
  29. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006;166:2073–2080
  30. Nambi V, Hoogevenn RC, Hu LCY, et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study, vol. 40. American Heart Association Inc.; 2009. p. 376.

PII: S0021-9150(09)00915-0

doi: 10.1016/j.atherosclerosis.2009.10.041

Atherosclerosis
Volume 210, Issue 1 , Pages 28-34 , May 2010

Article Tools

* Image Usage & Resolution